Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Daily Mirror
Daily Mirror
National
Martin Bagot

New 'variant proof' Cambridge University Covid jab receives backing worth millions

A new “variant proof” coronavirus vaccine by Cambridge University has received global backing worth millions of pounds.

Prime Minister Boris Johnson hailed the project to develop the “NextGen” jab against known and future variants.

He spoke via video link at the opening of a conference of the Coalition for Epidemic Preparedness Innovations (CEPI) in London which is partnering with the university to make the jab.

CEPI will invest up to £32million towards a version of mRNA technology already used in Moderna and Pfizer jabs that could be quickly modified to target new pathogens.

Mr Johnson said: “The UK is proud to have committed to a quarter of a billion pounds to support CEPI at the start of the pandemic, because it was precisely the partnership between CEPI, government, industry and academia which helped our vaccines to triumph over the virus.

Boris Johnson hailed the project to develop the 'NextGen' jab against known and future variants (PA)

“And now, we must come together to support CEPI’s global plan for the next generation of vaccine technologies, such as the new variant-proof vaccine being developed at Cambridge University to help protect us against the next Covid variant, or indeed, against the next pandemic.”

DIOSynVax, a university spin-off company, is working with the structure of proteins, computational biology and on boosting the immune system to work out how vaccines can be used to their best effect.

If the plan works, experts believe that vaccines could rapidly be developed against “Disease X” - unknown pathogens that have yet to emerge but which could cause pandemics.

Dr Richard Hatchett, chief executive of CEPI, said: “The UK Government and the country’s world-leading scientific institutions have been pivotal to the global response to Covid-19.

A person receives a Covid-19 vaccine (REX/Shutterstock)

“From the development of the CEPI-supported Oxford/AstraZeneca vaccine - which is used in more countries than any other - to the ground-breaking Recovery trial to evaluate life-saving treatments like dexamethasone, British science has played a leading role in protecting the world from Covid-19.

“I am excited to further strengthen CEPI’s strong ties to British science through this partnership with DIOSynVax.”

Professor Jonathan Heeney, chief executive of DIOSynVax, said: “Our approach is to be ahead of the next pandemic.

“To deliver custom-designed, immune selected vaccine antigens - which is ideal to prevent diseases caused by complex viruses such as the large and diverse family of coronaviruses.

“If successful, it will result in a safe, affordable NextGen vaccine for widespread use.”

England’s chief medical officer, Professor Sir Chris Whitty, told the CEPI conference the world had had many “near misses” with pandemics, and preparation for the next one was key.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.